NCT01121081

The Effect of Algae Dunaliella Bardawil on Psoriasis (2)

A Randomized, Double-Blind, , Placebo Controlled, 18 Week Study To Evaluate the Efficacy of Adjuvant 9-cis-β-Carotene Rich Powder of the Alga Dunaliella Bardawil in Subjects With Plaque Type Psoriasis Treated by Narrow Band UVB Therapy

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Sheba Medical Center · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a Randomized, Double-Blind, , Placebo Controlled, 18 Week Study To Evaluate the Efficacy of adjuvant 9-cis-β-Carotene Rich powder of the Alga Dunaliella bardawil in Subjects With Plaque type Psoriasis treated by Narrow Band UVB therapy.

Detailed description

This is a double blind, parallel group, randomized study with 12 weeks of daily oral administration of Dunaliella or placebo in psoriasis patients undergoing phototherapy. Subjects will be screened for eligibility at the baseline visit for phototherapy and blood tests. After screen phase of maximum two weeks the subjects will be randomized at phototherapy treatment no. 4 in to one of two treatments groups (2:1): Dunaliella or placebo. Each subject will have a final evaluation 4 weeks after the end of study drug treatment .

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Alga Dunaliella Bardawil	4 capsules per day, 2 in the morning 2 in the evening for 3 month
DRUG	Placebo	Drug: Alga Dunaliella Bardawil 4 capsules per day, 2 in the morning 2 in the evening for 3 month

Timeline

• Start date: 2010-01-01
• Primary completion: 2011-01-01
• Completion: 2012-01-01
• First posted: 2010-05-12
• Last updated: 2013-01-24

Locations

1 site across 1 country: Israel